Parkman Healthcare Partners’s Terns Pharmaceuticals TERN Stock Holding History

Parkman Healthcare Partners’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-620,877	Closed	-$25.1M	–	111
2025 Q4	$25.1M	Sell	620,877 -313,883	-34%	-$7.25M	2.39%	12
2025 Q3	$7.02M	Buy	934,760 +116,952	+14%	+$747K	0.73%	51
2025 Q2	$3.05M	Sell	817,808 -141,895	-15%	-$443K	0.35%	72
2025 Q1	$2.65M	Buy	959,703 +130,598	+16%	+$533K	0.31%	69
2024 Q4	$4.59M	Buy	829,105 +283,354	+52%	+$1.92M	0.61%	47
2024 Q3	$4.55M	Buy	545,751 +155,481	+40%	+$1.28M	0.58%	56
2024 Q2	$2.66M	Buy	+390,270	New	+$2.36M	0.36%	68
2023 Q4	–	Sell	-41,728	Closed	-$210K	–	104
2023 Q3	$210K	Sell	41,728 -60,697	-59%	-$385K	0.04%	102
2023 Q2	$896K	Buy	102,425 +27,425	+37%	+$320K	0.16%	88
2023 Q1	$888K	Buy	+75,000	New	+$717K	0.19%	73

Other funds holding TERN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Parkman Healthcare Partners's TERN Position: Q1 2026 in Review

Parkman Healthcare Partners sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 620,877 shares — an estimated $25.1M sold.

Parkman Healthcare Partners first reported a position in TERN in Q1 2023 and held it in 10 quarters. The position peaked at $25.1M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Parkman Healthcare Partners reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Parkman Healthcare Partners sold 620,877 Terns Pharmaceuticals shares in Q1 2026, an estimated $25.1M.
Parkman Healthcare Partners first reported a position in Terns Pharmaceuticals in Q1 2023 and held it in 10 quarters.
Parkman Healthcare Partners's Terns Pharmaceuticals position peaked at $25.1M in Q4 2025.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.